etoposide,doxorubicin,rituximab
Roche
[]
chamuleau - rcodoxm / rivac (rc/i) v da-epoch-r in 1l high risk burkitt
- 84 pts (aim &gt; 200), hiv + or -
- equiv efficacy
- more hosp days, tox &amp; blood prod use rc/i
- cns rel rates not avail
not sure practice changing (i would still use rc/i in young high risk). #eha2022 
Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Past chair of UK Hodgkin and T-cell study groups.